Biotech Values

[DewDiligence]

IDIX – Do you think the market is now discounting IDX899 because [IDIX] partnered with gsk?

Perhaps, to some degree. GSK is a name that’s more closely associated with the HIV market from two decades ago than the HIV market of today.

In the next few months—no later than the 1Q08 CC—I expect GSK to begin talking about its new plans in HIV. If they talk about rejuvenating the Epzicom franchise, that will be bearish, but if they emphasize how IDX899 can bolster GSK’s HIV pipeline, that will be bullish.

Comments?